OrthoPediatrics Corp. (NASDAQ:KIDS) Shares Bought by Wellington Management Group LLP

Wellington Management Group LLP grew its position in shares of OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) by 20.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,061,299 shares of the company's stock after purchasing an additional 178,078 shares during the quarter. Wellington Management Group LLP owned approximately 4.37% of OrthoPediatrics worth $24,601,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in KIDS. R Squared Ltd acquired a new position in OrthoPediatrics in the 4th quarter valued at $48,000. KLP Kapitalforvaltning AS acquired a new stake in shares of OrthoPediatrics in the fourth quarter valued at about $79,000. AlphaCentric Advisors LLC purchased a new position in shares of OrthoPediatrics in the fourth quarter worth about $171,000. Wells Fargo & Company MN boosted its position in OrthoPediatrics by 31.1% during the fourth quarter. Wells Fargo & Company MN now owns 9,853 shares of the company's stock worth $228,000 after acquiring an additional 2,338 shares during the last quarter. Finally, HighTower Advisors LLC purchased a new stake in OrthoPediatrics during the 4th quarter valued at about $268,000. 69.05% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other OrthoPediatrics news, CFO Fred Hite sold 6,443 shares of OrthoPediatrics stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $160,172.98. Following the transaction, the chief financial officer now owns 207,989 shares of the company's stock, valued at $5,170,606.54. The trade was a 3.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Gregory A. Odle sold 5,359 shares of the company's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $133,224.74. Following the completion of the sale, the insider now directly owns 148,788 shares of the company's stock, valued at $3,698,869.68. The trade was a 3.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 23,732 shares of company stock worth $589,978. 32.70% of the stock is currently owned by insiders.

OrthoPediatrics Stock Down 0.9%

Shares of OrthoPediatrics stock traded down $0.18 during trading hours on Wednesday, reaching $20.26. 20,122 shares of the company were exchanged, compared to its average volume of 197,658. The company has a debt-to-equity ratio of 0.19, a quick ratio of 3.68 and a current ratio of 7.17. The firm has a market cap of $492.05 million, a PE ratio of -16.47 and a beta of 1.09. The stock's fifty day moving average is $21.91 and its 200 day moving average is $23.53. OrthoPediatrics Corp. has a 1 year low of $19.52 and a 1 year high of $35.99.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.13). OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. The firm had revenue of $52.41 million for the quarter, compared to analysts' expectations of $51.68 million. As a group, equities research analysts forecast that OrthoPediatrics Corp. will post -0.93 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Truist Financial lowered their target price on OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating on the stock in a report on Friday, April 11th. Piper Sandler lowered their price objective on OrthoPediatrics from $40.00 to $30.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. Lake Street Capital began coverage on OrthoPediatrics in a research note on Monday, April 7th. They issued a "buy" rating and a $37.00 target price for the company. Stifel Nicolaus lowered their price target on shares of OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, March 5th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $42.00 price objective on shares of OrthoPediatrics in a report on Thursday, May 8th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $35.83.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.